Arginine-vasopressin (AVP) immunoreactivity (Ir) 
Introduction
Immunoreactive plasma arginine-vasopressin (IrAVP)' has been found to be elevated in platelet-rich plasma (PRP) by at least two groups of investigators using different plasma extraction procedures and different specific antisera against AVP (1, 2) . It is also known that large doses ofAVP aggregate platelets in vitro through VI receptors (3) and detailed pharmacological studies of these human platelet vasopressin receptors have recently been reported (4, 5 Methods Plasma A VP and platelet A VP RIA of arginine-vasopressin. Plasma and "platelet-fraction" argininevasopressin were obtained according to a modification of the method described by Preibisz et al. (1) . Two blood samples (A and B), of 5 ml each, were obtained at each collection period and drawn in chilled EDTA containing tubes. Sample A was centrifuged at 40C, 110 g for 20 min; 100 Ml of plasma was then removed and the platelet content of this fraction was determined (Coulter counter, model P-64, Coulter Electronics Inc., Hialeah, FL). 1 ml ofplasma was then frozen at -20°C and extracted within 2 to 3 wk with the acetone-petrol-ether method (6) . 100 A plasma samples were randomly obtained during these studies and their platelet content was 288,000±15,000 Ml. The plasma vasopressin concentration measured in these samples was called "platelet-rich" plasma vasopressin fraction. Sample B was centrifuged at 4°C, 950 gfor 20 min; 100 plasma samples B obtained during these studies contained 31,000±2,500 platelets/Al. The plasma vasopressin concentration measured after extraction in these samples was called "platelet-poor" plasma vasopressin fraction or plasma arginine-vasopressin. The platelet-rich vasopressin fraction minus the platelet-poor vasopressin fraction was called PlatAVP.
AVP was measured by a RIA developed in our laboratory (7, 8) . In all the experiments described here, the RIA sensitivity was 0.1 pg/tube and a 50% displacement of the tracer was obtained for 1.2 pg/tube. The antiserum used did not crossreact with dDAVP up to 100 pg/tube.
High performance liquid chromatographic (HPLC) analysis ofPlatA VP, Pavp, and synthetic A VP 27324, Waters Associates) and run at room temperature. A Guard-Pak precolumn module with disposable silica precolumn inserts was always used.
Two elution systems were chosen (9, 10): (a) trifluoroacetic acid (TFA)-acetonitrile, pH 3.5: a linear gradient of 10-50% B was used. Solvent A was 0.1% TFA pH 3.5 and solvent B 75% acetonitrile in 0.1% TFA; (b) Ammonium acetate (Amm Acet)-methanol, pH 6.5: a linear gradient of 40-67% B was used. Solvent A was 0.05 M Amm Acet pH 6.5 and solvent B was 75% methanol in 0.05 M Amm Acet.
In control experiments we determined that, in these two elution systems, tritiated arginine-vasopressin (40 Ci/mM, New England Nuclear, Boston, MA), at a concentration range from 25 to 75 pg (2,500 to 7,500 dpm) was eluted following a constant pattern.
The elution reagents were HPLC grade (Fisher or Canlab, Montreal, Qu6bec, Canada). All the solutions used in this HPLC analysis were filtered through a 0.45-Mm filter (Millipore, Mississauga, Ontario, Canada, or Sartorius, Palaiseau, France) and degassed. Before the injection of any sample, the column was equilibrated with the initial conditions for at least 1 h and a control gradient, i.e., without any injection, was performed. Following each gradient with an injection, a linear gradient up to 99% B was performed to "wash" the column.
The flow rate was 1 ml/min and the samples were eluted during 40 min. The samples from the control and from the experimental gradients were collected every minute and, after evaporation to dryness, resuspended in assay buffer. IrAVP was then measured in duplicate in each collected fraction. For this purpose, and to control for the possible interference in our RIA system of nonvolatile products like Amm Acet or TFA, standard curves for the AVP RIA were pipetted in the final composition of the two elutions systems used, evaporated to dryness, and reconstituted in assay buffer. Neither of the two elution systems used interfered significantly with our RIA of AVP but the sensitivity was 0.5 pg/tube of AVP for acetonitrile-TFA and 0.1 pg/tube for Amm Acetmethanol.
Thin layer chromatographic (TLC) analysis ofsynthetic A VP, Pavp, PlatA VP, and tritiated A VP Synthetic AVP was added to a pool of PRP from patients with central diabetes insipidus and extracted with acetone and petrol-ether as previously described (7) . Plasma AVP, i.e., AVP in platelet-poor plasma was concentrated 12 times and PlatAVP was obtained as previously described. Appropriate controls with corresponding protein concentrations were prepared by the addition of [3H]AVP in the platelet-poor or plateletrich pool of plasma of patients with central diabetes insipidus.
We used TLC plates from Whatman, Inc., Clifton, NJ). 50-Ml samples corresponding to 20-25 pg of the AVP compound were layered. The developing solvent was a mixture of n-butanol, pyridine, glacial acetic acid, and water (15 vol/10 vol/3 vol/6 vol) and the chromatographic analysis for vasopressin was developed during 7-8 h at4C. The migration front was carefully identified and the plate was dried. Each silica plate was then divided into 0.5 cm-width bands. The powder from each band was collected, mixed in 1 ml of0.1 N formic acid for elution and agitated during 15 h at room temperature. Each tube was then centrifuged and the supernatant was collected and evaporated. The dry residue was resuspended in assay buffer and IrAVP was measured. Standard curves for the AVP RIA were also pipetted in 0.1 N formic acid, evaporated to dryness and resuspended in assay buffer. In these conditions, the sensitivity of the assay was found to decrease to 0.5 pg of AVP per assay tube but precise standard curves were obtained for concentrations between 0.5 and 10 pg/tube. In control experiments, we determined that [13H]AVP migrated reliably using the above conditions. For each unknown compound, retardation factors (Rd) were calculated and compared to correspondingly concentrated tritiated controls.
Waterload and hypertonic saline infusions in 9 normal subjects Measurement ofPavp and PlatA VP. Nine normal subjects (aged 22-28, 4 men and 5 women), after an overnight fast, received a 20 ml/kg body wt waterload administered in 30-40 min, followed 2 h later by a 3% saline infusion at 0.1 ml/kg body wt per min. Blood and urine samples were obtained every 30 min during the test. Plasma osmolality plasma sodium, urinary osmolality, Pavp, and PlatAVP were measured with methods previously described (7, 8 
Binding studies of[3HIA VP on intact human platelets
We prepared a human platelet suspension according to Haslam and Rosson (12) immediately before each binding experiment. Nine normal subjects (five men, four women) participated and a total of 16 binding studies were performed. Blood samples (50-100 ml) were collected in a citrate phosphate dextrose adenine solution. Blood was centrifuged at 200 g (15 min, room temperature) and PRP was separated from red blood cells. The PRP was then further centrifuged at 2,000 g (15 min, room temperature). Platelet pellets were then washed two times with phosphate buffer solution (PBS, pH = 7.4, 290 mosmol/liter) and finally resuspended in PBS. Two 100-Ml samples of PRP and two I00-Al samples ofthe final platelet suspension were used for platelet counting. The protein content of the final platelet suspension was measured in 2 X 500 Ml samples using the Lowry method. PRP had 476,000±48,000 platelets/ A1; the platelet suspensions contained 300,000±57,000 Ml and 411±77 mg protein/ml, representing a relationship of 1.42±0.24 mg protein/109 platelets in accordance with previous measurements (13).
Binding assays were performed at 30°C during 30 min. Triplicate samples were incubated in 4-ml polyethylene tubes (Sarstedt, Inc., Princeton, NJ), with gentle shaking in a Dubnoff incubator in a final volume of 500 Ml. Incubation conditions were 1 mM CaCI2, 2.6 mM KCI, 1.47 mM KH2PO4, 0.5 mM MgCI2 6H20, 136 mM NaCl, 8 by passing each medium through a PBS presoaked filter (Whatman GF/C, 24 mm) and by rinsing with 2 X 5 ml of4°C PBS. Filter associated radioactivity was measured by liquid scintillation counting (Econofluor, New England Nuclear, and LS3801 counter, Beckman Instruments, Inc., Fullerton, CA) after an overnight air dryness evaporation. Specific binding was evaluated as the differences between total (without cold AVP) and nonspecific binding (with cold 10-6 M AVP). Nonspecific binding did not represent > 30% oftotal binding. Results were analyzed by Scatchard (14) and Hill (15) In preliminary experiments, we determined that vasopressin binding to intact platelets was time dependent during a 40-min observation period, reaching an equilibrium in 20 min. The number of platelets incubated (10 X Results are given as mean±SEM unless otherwise indicated.
These studies were approved by the Ethics Committee at HOpital du Sacre-Coeur in Montreal and all subjects gave informed consent.
Results
HPLC and TLC ofplasma and "platelet-rich" plasma A VP Ir. In the first elution system used, synthetic AVP, plasma AVP and platelet AVP eluted in a major peak in fractions 25 and 26 (24-24.75% acetonitrile) (Fig. 1) . At least two experiments for each compound were performed and identical results were ob- tritiated AVP since a major peak was obtained in fractions 20 and 21 (38.5 to 39% methanol) and a minor peak (10% of total) was observed for each of the compounds in fraction 37 (47% methanol) (Fig. 1) . At least two experiments for each compound were performed. Also, when the peak ofthe first HPLC analysis (acetonitrile) for tritiated, plasma, and platelet vasopressin was subjected to the second elution system (methanol), a single peak was observed in fractions 20 and 21. In TLC experiments, the mobility ofplasma and platelet AVP were also found to be identical as compared to the reference compound (Table I) . Pavp and PlatA VP during waterload and hypertonic saline infusion in nine normal subjects (Fig. 2) (Table II) . A PlatAVP concentration of 5 pg/ml was estimated to represent a true platelet-AVP concentration of 500 pg to 4,000 pg/ml (i.e., 0.463 X 10-9 M to 3.7 X 10-9 M). 5 pg of PlatAVP was also estimated to represent nine molecules of AVP for each individual platelet.
Pavp and platelet-rich plasma Ir after vasopressin administration in four patients with diabetes insipidus (Fig. 3) . The intravenous administration of 1 mU/kg of vasopressin resulted in identical platelet-poor plasma vasopressin Ir and PRP vasopressin Ir (upper part of Fig. 3) . However, the subcutaneous administration of 5 U of Pitressin induced significantly higher PRP vasopressin Ir suggesting that a significant portion of circulating vasopressin was then associated with the platelet fraction (lower part of Fig. 3 
Discussion
The present study confirm earlier findings using radioimmunoassay techniques that Ir plasma AVP concentration is higher in PRP as compared to platelet-poor plasma. This difference has been found in normal individuals, hypertensive, and congestive heart failure patients (1, 2, 7) . Also, Pavp and PlatAVP have been found to be absent in four patients with central (neurogenic) DI (7).
The results of the present study extend these accumulated proofs that IrAVP in PRP is indeed true AVP associated with the platelet fraction. The fact that PlatAVP, Pavp, and synthetic AVP eluted in identical fractions from the HPLC column on two different elution systems and behave similarly on TLC analysis would suggest an identical biochemical behavior suggestive of a similar structure.
Our results also provide measurements of PlatAVP during osmotic stimulation in man as well as measurements of PlatAVP after AVP administration in patients devoided of endogenous AVP. It was hypothesized, on the basis of recent in vitro results (4, 5) that AVP could be associated to platelets through a specific V1 vascular receptor. AS a consequence, acute osmotic stimulation or suppression will have little effect on PlatAVP; on the other hand, large doses of exogenous AVP could eventually bind to a specific platelet receptor. In favor of our hypothesis, we found that during a standard waterload and hypertonic saline infusion test, significant variations ofPavp were observed without any significant variations of PlatAVP (Fig. 2) . Also, as described in Fig. 3 , small intravenous doses of AVP were insufficient to bind to platelets; by contrast, large doses ofAVP clearly increased PlatAVP as compared to Pavp.
Analysis of the individual responses to the osmotic stimulation in normal subjects demonstrated a significant correlation between the slope of the relationship Pavp/Posm and PlatAVP (Table II) . The following schematic view of the association of AVP to platelets could thus be proposed: moderate to large concentrations of plasma AVP will bind to platelets and the absolute amount called "PlatAVP" could be an index of the long term stimulation of AVP. The higher the slope of the relationship Pavp/Posm, the more AVP would be released during small increase in Posm and thus could be bound to platelets. This interpretation is also consistent with our results in a series of patients with severe congestive heart failure (7). In these patients, high Pavp levels were associated with high PlatAVP. Improvement of cardiac hemodynamics decreased Pavp and PlatAVP. Thus, both chronic osmotic and nonosmotic stimulation could determine the absolute PlatAVP concentration in man. Since PlatAVP was the substraction of IrPRP minus Pavp, we also calculated the "true" platelet AVP concentration. Considering the very minimal amount of volume occupied by platelets in 1 ml of plasma, we calculated an intraplatelet AVP of 500 pg to 4,000 pg/ml or 0.463 X l0-9 M to 3.7 X 10-9 M (see Methods).
We then tried to compare these values to the in vitro results obtained from binding studies on intact platelets. In accordance with recent results from two other groups (4, 5), we found binding characteristics corresponding to the above in vivo values: in this regard, the association constant of [3H]AVP to intact human platelets: Kd = 0.72±0.27 nM was entirely compatible with the intraplatelet AVP concentration previously calculated (0.46 X 10-9 to 3.7 X 10-9 M). Our pharmacological study using two analogues also suggested, in accordance with two recent extensive publications (4, 5) The results of the present study raised a number ofpractical and theoretical new points in regard to measurements and significance of Pavp and PlatAVP. PlatAVP could be an integer over time of the long-term release (osmotic and nonosmotic) of vasopressin. Thus, a single PlatAVP measurement could eventually give some information about the long-term stimulation of the AVP system. This assertion seems to be true in chronic congestive heart failure where improvement in cardiac hemodynamics, over a 2-d period, decreased Pavp and PlatAVP (7) . The effect of long-term chronic osmotic stimulation (as for example in congenital nephrogenic diabetes insipidus) have not been so far examined. Other observations and experiments will be necessary to determine the fate of PlatAVP: for example, vasopressin intraplatelet processing and possible release are completely unknown at the present time.
In summary, we recommend that measurements of plasma immunoreactive AVP should be done in platelet-poor plasma and PRP. Pavp (in platelet-poor plasma) could be considered as a measurement of circulating biologically important AVP and should be related to Uosm (with normal renal function). PlatAVP may be an index of the long term stimulation of AVP (osmotic and nonosmotic) and a direct measurement of AVP bound to a specific platelet receptor.
